Through Alimta Lens, OSI Views Positive Near-term Advantages For Tarceva In Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of Lilly’s Alimta in first-line NSCLC and recent data showing it is ineffective in squamous histologies could give Tarceva a leg up in second-line setting.